SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
AVANIR Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Agitation in Patients With Alzheimer's Disease